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Abstract
The initiation of Crohn’s disease, an inflammatory bowel disease, has been 
primarily associated with crypt inflammation and abscesses, which further pro-
gresses towards the development of mucosal lesion and ulcers followed by mucosal 
edema. Despite many years of research for the confirmatory role of inflammation 
in this disease, various pathways and diagnosis for this inflammatory cascade is 
still unrevealed, which in fact is of utmost importance in the assessment of disease 
activity and for tailoring the therapy. Till now, various histopathological as well 
as endoscopic examinations has been found to be effectively and accurately assess 
inflammatory activity, but they are invasive, time consuming and expensive 
and therefore are unsuitable for routine use. Consequently, the latest research is 
focusing on various biomarkers of intestinal inflammation and the corresponding 
biological therapy. So, this chapter will cover the recent advances in diagnosis and 
pharmacological therapies for the same.
Keywords: inflammation, biological therapy, fibrostenosis, stricture,  
immune response
1. Introduction
Crohn’s disease (CD) is a chronic, inflammatory disease, mainly affecting the 
gastro-intestinal tract and is usually characterized as relapse-remitting condition 
with progressive bowel damage [1, 2]. Being first discovered in 1932 in the United 
States, its rising prevalence in Europe, North America and developing countries 
of East Asia and South America during the 20th century is of serious health con-
cern [3–6]. The complex etiology of CD is still unresolved and the pathogenesis is 
supposed to involve various genetic, environmental, gut-mucosal and immune-
mediated factors which ultimately causing the initiation of inflammatory cascade 
followed by altered epithelial barrier function and mucosal damage [7–9]. CD 
represents bowel inflammation at the time of diagnosis but with disease progres-
sion, various complications such as fibrotic stenosis and strictures occur which lead 
to the bowel blockages [10]. Several cohort studies have reported that in about 80% 
of the patients, CD is characterized by inflammation and approximately 5–28% of 
them presents with fibrotic structuring [11–13]. Also, in case of CD complications, 
the additional surgery cost presents a huge socioeconomic burden in developed as 
well as developing countries [6, 14].
The diagnosis of crohn’s disease (CD) in clinical settings is still challenging 
because of the lack of accuracy and specificity of the currently available diag-
nostic tools, various serological, genetic and inflammatory biomarkers. Also the 
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heterogeneous nature of various fibrotic and inflammatory pathways involved in 
the disease limits the scope of such techniques [15, 16]. Preceding the inaccessibility 
towards the deep fibrotic site while using the invasive, expensive and time consum-
ing conventional endoscopy, several advances have been made in the diagnosis of 
CD from both diagnostic and therapeutic perspectives. Diagnosis, disease activity, 
and therapeutic response are currently assessed by endoscopy, cross-sectional 
imaging, and biomarkers. Furthermore, because of paucity of effective drugs to 
treat inflammatory as well as complicated CD, a step-up approach of therapeutic 
management is required to not only to decrease disease activity but also to improve 
quality of life of the suffering population in clinical practice. Considering these 
points, this book chapter will discuss the recent advances in diagnosis and  
management of CD.
2. Diagnostic approach
2.1 Endoscopy and serological tests
Till now, the diagnostic process in clinical settings completely relied on various 
conventional techniques such as endoscopy and serological tests [7, 17]. Various 
antibodies against microbial antigens such as anti-Saccharomyces Cerevisiae 
antibodies (ASCA), outer membrane porin (anti-OmpC), flagellin (anti-Cbir1), 
and Pseudomonas flourescens- associated sequence 1–2 (anti-12) etcetera has been 
found to be involved in altered microbial biota in CD patients. IgA anti-OmpC, IgG 
anti-Cbir1 and IgA anti-I2 were found to be positive in approximately 55% of CD 
cases [18–20]. Furthermore, the elevated serum levels of various new antiglycan 
antibodies such as anti-aminaribioside (ALCA), anti-mannobioside carbohydrate 
antibody (AMCA) and anti-chitobioside carbohydrate antibody (ACCA) in CD 
patients has been remained an indicator for these antibodies as diagnostic bio-
markers in patients suffering from CD [21]. A meta- analysis by Kaul et al., 2012, 
reported positive correlation between the number of positive anti-glycan antibodies 
and disease severity [22].
2.2 Inflammatory markers
As inflammation plays a prominent role in the initiation and progression of 
Crohn’s disease, so determination of inflammatory state is crucial for the assessment 
of disease activity and for tailoring therapy. Non-invasive inflammatory markers 
such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) have 
been used for these indications. CRP, an acute phase protein, produced primarily by 
hepatocytes in response to inflammatory trigger mediated by various other cyto-
kines such as interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α, has proven 
its role as inflammatory biomarker from past decades but has since fallen out of 
favor as they are generally non-specific. More recently, markers of inflammation 
that are specific to the GI tract, such as fecal calprotectin (FC) and stool lactoferrin 
(SL), have been introduced as well established biomarker of intestinal inflamma-
tion. Various studies have reported the positive correlation between increased levels 
of FC and CD progression [23, 24]. In addition another research has documented 
that the increased levels of CRP, ESR in combination with fecal calprotectin proves 
best biomarker for the early diagnosis of crohn’s disease in children suffering from 
abdominal pain and diarrhea [25]. Apart from this, various genetic biomarkers 
have evolved their role not only in the etiology of disease but also play a role in the 
disease pathogenesis as well as phenotype. Among genetic markers, the functional 
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polymorphs of the interferon regulatory factor 5 (IRF5) were found to affect the 
risk profile for CD [26]. The assessment of serological biomarkers and inflamma-
tory biomarkers as an adjunct to genetic biomarkers such as extracellular matrix 
protein −1 (ECM1), signal transducer and activator of transcription 3 (STAT3) 
etcetera could help in the early diagnosis of complications associated with [27].
2.3 Advanced imaging techniques
Imaging techniques provides the platform not only to understand the pathol-
ogy of the disease but are also able to provide detailed note about the molecular 
mechanism involved in the disease, thus helps in aiding better therapeutic deci-
sions about the disease. Among conventional techniques, Barium follow-through 
(BaFT) has been used to diagnose luminal small bowel CD [28]. Nowadays, these 
have been replaced by new endoscopic developments such as double balloon 
endoscopy and capsule endoscopy as BaFTs assess only the intraluminal mucosal 
pathology, meanwhile obscuring the lesion caused by superimposition of the 
bowel loops. The development of cross-sectional imaging technologies facilitates 
the accurate and rapid assessment of not only the small bowel and adjacent tissues 
but also assess deep layers for strictures and extraintestinal complications such as 
abscesses & fistulas. Also the shift from techniques causing exposure of ionizing 
radiation such as computerized tomography (CT), towards safe non-radiating, 
non-invasive, cost efficient and safe cross sectional techniques such as ultrasound 
(US) and magnetic resonance imaging (MRI) have changed the clinical perspec-
tive towards the disease complication. The modified version of these techniques 
such as computerized tomography enterography (CTE), intestinal ultrasound 
(IUS), magnetic resonance enterography (MRE), contrast enhanced ultraso-
nography (CEUS) etcetera has been preferred diagnostic tools even for the early 
prediction of CD complications [29, 30].
2.3.1 Computed tomography enterography (CTE)
After its discovery in 1977 to assess the extent and severity of CD, CTE has 
evolved its role in the diagnosis of intraluminal and extraintestinal complications 
involved in CD patients [31, 32]. Moreover, it differs from the conventional abdomi-
nal CT scan techniques in a way that it involves the intake of enteric or oral contrast 
medium to achieve adequate luminal distension [33]. This technique involves the 
use of small bowel distension along with the mixture of low density or neutral 
contrast agents and an abdominal CT examination following the administration 
of intravenous contrast agents [29]. Apart from enabling the dynamic imaging, 
CTE provides additional advantages such as lower cost, lesser influence of bowel 
peristalsis, wide availability, and greater patient safety with lesser need of general 
anesthesia and better efficacy in patients sensitive to MRI [31]. However, the use of 
ionizing radiation make its use little disadvantageous but various new techniques 
has been developed which makes CT examinations at significantly lesser radiation 
rate in pediatrics and adolescents [34–36].
2.3.2 Small bowel ultrasound (SBUS)
This inexpensive, non-radiating and well-tolerated technique provides detailed 
evaluation of bowel and abdominal viscera [37]. This technique has been preferred 
for pediatric and young non-obese patients as obesity obscure the thorough exami-
nation. Irrespective of its dependency for use on special training and practice, it is 
still considered comparable to endoscopy and MRE [38, 39].
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2.3.3 Magnetic resonance enterography (MRE)
As per the American College of Radiology’s Appropriateness Criteria, MRE 
has become first line of choice for evaluating children or young patients of CD 
[40]. Also a recent study has demonstrated its greater sensitivity and specificity as 
compared to US and its superiority for disease mapping over other techniques [41]. 
Several studies have compared the use of CTE and MRE and reported that both the 
techniques have similar sensitivities and specificities in diagnosing CD [29, 42]. 
MRE has been reported to be more advantageous because of absence of ionizing 
radiations, high tissue contrast resolution, and less adverse effects because of use 
of intravenous contrast materials [29]. However, MRE technique also has some 
disadvantages including longer acquisition time, hindrance due to peristalsis and 
bowel movements and it has been found to be more expensive, time-consuming, 
and less well-tolerated than SBUS and CTE [31, 43].
Thus proteomics has emerged as an attractive approach not only to define the 
pathogenesis of disease but also to distinguish inflammatory and fibrostenotic 
phenotypes and predict the complications at an earliest. Coupling these protein 
biomarkers through proteomics with various non-invasive, non-radiating imaging 
techniques may aid in better diagnosis of CD and may provide a novel approach for 
the treatment of CD.
3. Therapy approach
3.1 Conventional therapeutic approach
The etiology and pathogenesis of CD is still complex and unresolved, curbing 
the development of new therapeutic agents for its treatment. The remission and 
recurrence of disease demands the effective induction and maintenance therapy 
while reducing the disease complications and improving the quality of life. Till date, 
aminosalicyclic acids, corticosteroids and various immunomodulators has been 
considered as therapeutic agents of choice, but lack of efficacy because of hetero-
genecity of disease and higher toxicity profile of these drugs have made these drugs 
inappropriate.
Among aminosalicylates, sulfasalazine and mesalamine has been effective in 
the treatment of CD. Various clinical studies have reported the role of sulfasalazine 
(3–6 gm/day) in the remission of mild to moderate CD [44, 45]. Mesalamine has 
been used routinely for decades in patients with Crohn’s disease in clinical practice. 
A recent study have demonstrated that mesalamine at doses above 2.4 g/d was 
more effective than placebo for the induction of remission of Crohn’s disease [46], 
but owing to less benefits, this class has gone out of favor in clinical practice [47]. 
Even various systematic reviews and meta-analyses remained inconclusive about 
the role of ASA in remission of active CD and preventing relapse of CD [48, 49]. 
Furthermore, broad spectrum antibiotics have been considered to be clinically 
efficacious as compared to narrow spectrum since the strain of intestinal bacteria 
involved in the progression of CD is still uncertain [50]. So, various clinical trials 
have reported the efficacy of antibiotics such as metronidazole, ciprofloxacin, 
clarithrmycin, rifaximin and anti-tuberculous regimen for the treatment of mild to 
moderately active CD [51, 52]. Rifaximin have shown its efficacy against majority 
of intestinal flora with relatively infrequent bacterial resistance. On the same pace, 
it has shown its effectiveness in CD with ciprofloxacin 500 mg, orally twice daily, 
given for the duration of 6 months [53]. Furthermore, a randomized controlled trial 
has shown the significant clinical efficacy with metronidazole [54]. As per recent 
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study, low-dose metronidazole in dose of 250 mg t.i.d. for the duration of 3 months 
even reduces the endoscopic postoperative recurrence rates in crohn’s disease [55]. 
Moreover, Metronidazole in combination with ciprofloxacin 500 mg bid have 
shown promising rate of remission [56]. Furthermore, rifaximin, another broad 
spectrum antibiotic was found to be efficacious in various clinical trials. The double 
blind randomized controlled trials (RCT) were conducted by Prantera and cowork-
ers 2006 & 2010. In these RCT’s, 83 patients having 800 b.i.d. dose & 402 patients 
having 400–1200 b.i.d dose respectively for the duration of 3 months, have shown 
promising remission rate in CD [57, 58]. Various other studies have also demon-
strated the same effects of rifaximin, in the dose of 800 mg b.i.d for the duration of 
3 months [52, 59, 60].
Furthermore, corticosteroids were included in the algorithm of CD therapy. 
An accumulative body of literature has reported the preference of corticosteroid 
efficacy over conventional steroids and ASA’s in CD, especially for ileocecal and 
ileal diseases [61–63]. Budesonide in combination with ciprofloxacin and metroni-
dazole have shown effectiveness in induction of remission in CD patients but again 
the higher frequency of serious adverse reactions do not favor their use as routine 
therapy [64]. Moreover, the available data are limited to small uncontrolled trials 
that have not consistently demonstrated efficacy with these agents at inducing 
clinical remission for mild to moderate CD [54]. In addition, they are associated 
with a high potential for dependence and serious adverse effects [62, 65]. So, the 
rising detrimental effects of corticosteroids, which once has been used as first line 
therapy from the past decades, has led to stringent attempts to limit their use in the 
treatment of CD.
3.2 Advanced therapeutic approach
CD pathogenesis involves the breaching of epithelial barrier of mucosal layer 
and luminal microflora tend to stimulate the pro-inflammatory immune response 
leading to release of various proinflammatory cytokines such as interferon-gamma, 
interleukin 12, TNF- α and [66, 67]. Biologics therapy has been approved by FDA 
for the treatment of inflammatory cascade long time ago but the discovery of new 
molecules in this arena is still continued and represents a major breakthrough in 
the treatment of CD. The advanced therapeutic approach includes biologic agents 
such as immunomodulators, anti-TNF- α agents, IL-12, IL-23 antagonists, anti-
adhesion molecules and monoclonal antibodies. Immunomodulators has been used 
primarily for inflammatory state of CD in clinical practice from many years. Among 
immunomodulators, Azathioprine (AZA) and 6-mercaptopurine (6-MP) has been 
included in the meta-analysis studies and have revealed their role in the remission 
in CD patients but with occurrence of serious adverse effects [68, 69]. On the other 
side, biologicals such as TNF-α antagonists and IL antagonists have been adopted 
for the treatment of CD complications such as fistulas and strictures. Moreover, 
these offer advantage over corticosteroids which tend to suppress the entire immune 
system and produce various adverse effects. Biologics target the inflammatory 
pathway specifically, with lesser unpredictable side effects. The US Food & Drug 
Administration (FDA) approved infliximab in 1998, followed by the approval of 
adalimumab and certolizumab. These TNF-α antagonist remained as an effective 
option among biologics since now for the treatment of CD. Systematic reviews and 
meta-analyses have evidenced about the role of adalimumab and infliximab in the 
maintenance and remission of CD [70–72]. Moreover, various optimization strate-
gies have been given regarding the use of anti-TNF agents in CD patients. Likewise, 
as per SONIC study, infliximab was found to be more efficacious when given 
in combination with azathioprine as compared to monotherapy [73]. Although 
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TNF-antagonist therapy has greatly improved the management of CD, these drugs 
have some important limitations [74, 75]. Also, Up to one-third of patients do not 
respond to induction therapy, and an additional 40% lose response over the first 
year [76]. Treatment with a second TNF antagonist in patients failing these agents 
has only modest efficacy [77]. Thus, a need exists for alternative therapies. So, in 
recent years, a range of newer molecules has been discovered and implemented 
in clinical practice. Among these agents, Vedolizumab and Ustekinumab have 
shown effective and safe profile in the induction and remission of CD [78, 79]. 
Vedolizumab, the selective leukocyte adhesion molecule inhibitor was approved for 
CD in 2014, followed by ustekinumab, the monoclonal antibody that targets inter-
leukin-12 and interleukin-23 in 2016. Furthermore, Pirfenidone and nintedanib 
which have been used for the treatment of pulmonary fibrosis have also proven 
their role in the management of fibrostenotic CD [80, 81]. Considering the efficacy 
of combination of immunomodulators with biologicals, it has been reported that 
inflixmab prescribed along with thiopurines is more efficacious as compared to 
infliximab alone or thiopurines alone [82].
Thus, 5-Aminosalicylic acid agents are not considered as first choice for treat-
ment of CD. Corticosteroids such as Budesonide and Prednisone are now-a-days 
considered as the first line agents. Broad spectrum antibiotics such as metroni-
dazole, ciprofloxacin, clarithrmycin and rifaximin have been considered to be 
clinically efficacious and remained as important adjuncts for the treatment of mild 
CD. Immunomodulators are used as second line agents in mild to moderate Crohn’s 
disease. They act by modifying the immune system while inducing and maintaining 
remission. Biologicals such as Adalimumab, Infliximab, certolizumab, Vedolizumab 
eand Ustekinumab are used in moderate to severely active CD.
4. Conclusions
On concluding remarks, the diagnosis as well as management of CD and 
associated complications should remain the ultimate goal. From diagnostic per-
spective, CTE and MRE are at the forefront and providing new ways to quantify 
disease activity in order to provide more personalized therapy in clinical practice. 
Furthermore, from the diagnostic perspectives, the continuous evolvement of 
biologicals such as anti TNF-α and IL-antagonists has been proven as revolution in 
the treatment of inflammation as well as various complications associated with CD. 
Although the current therapy available for CD meets the safety as well as efficacy 
data requirements, still there is need of newer agents with high efficacy, less side 
effects and improved pharmacodynamic as well as pharmacokinetic profile. So, the 
anticipated discovery of new diagnostic biomarkers and therapeutic agents while 
minimizing the use of conventional endoscopic and radiologic examination will 
enable physicians to provide individualized treatment plans in order to improve the 
long-term prognosis of patients suffering from CD.
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